Skip to content
lifestyle.houstonnewstoday.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
SOLIGENIX, INC.
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet’s Disease
February 26, 2026
Soligenix to Present at BIO Investment & Growth Summit
February 24, 2026
Soligenix Details Recent Progress and Upcoming Milestones
February 13, 2026
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet’s Disease Published in Rheumatology (Oxford)
December 18, 2025
←
Previous Page
1
2